Candel Therapeutics Inc (CADL)

01:50 AM

Candel Therapeutics secures $130M loan facility to advance clinical pipeline - ca.proactiveinvestors.com

01:50 AM

09:05 AM

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc - MarketScreener

09:05 AM

08:49 AM

Candel Therapeutics Secures $130M Loan for Trials - TipRanks

08:49 AM

08:47 AM

Candel Therapeutics secures $130M loan to advance cancer therapy trials - Proactive financial news

08:47 AM

08:36 AM

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - The AI Journal

08:36 AM

08:27 AM

Candel Therapeutics secures $130 million term loan facility - Investing.com

08:27 AM

08:22 AM

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - The Manila Times

08:22 AM

08:18 AM

Candel Therapeutics Incannounces encouraging interim data from CAN-3110 trial - MarketScreener

08:18 AM

08:14 AM

Candel Therapeutics Reports Promising Interim Data for CAN-3110 in Recurrent Glioblastoma and Publication in Science Translational Medicine - Quiver Quantitative

08:14 AM

08:06 AM

Candel Therapeutics Announces Positive Interim Data After - GlobeNewswire

08:06 AM

08:05 AM

Candel Therapeutics Reports CAN-3110 Pathologic CR, mOS 12.0 mo | CADL Stock News - Stock Titan

08:05 AM

02:20 AM

Can Candel Therapeutics Inc. stock sustain revenue growthMarket Sentiment Summary & Daily Chart Pattern Signal Reports - newser.com

02:20 AM

Oct 13, 2025

Candel Therapeutics Inc. stock retracement – recovery analysisEntry Point & High Accuracy Swing Trade Signals - newser.com

Oct 13, 2025

Oct 13, 2025

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha

Oct 13, 2025

Oct 11, 2025

Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com

Oct 11, 2025

Oct 11, 2025

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer - Stocktwits

Oct 11, 2025

Oct 10, 2025

What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com

Oct 10, 2025

Oct 10, 2025

Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com

Oct 10, 2025

Oct 10, 2025

How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat

Oct 09, 2025

Oct 09, 2025

Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in

Oct 09, 2025

Oct 09, 2025

Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com

Oct 09, 2025

Oct 09, 2025

Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com

Oct 09, 2025

Oct 07, 2025

Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com

Oct 07, 2025

Oct 06, 2025

How resilient is Candel Therapeutics Inc. stock in market downturns2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 06, 2025

Oct 06, 2025

Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com

Oct 06, 2025

Oct 05, 2025

Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com

Oct 05, 2025

Oct 03, 2025

Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news

Oct 03, 2025

Oct 03, 2025

Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times

Oct 03, 2025

Oct 03, 2025

Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative

Oct 03, 2025

Oct 03, 2025

Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan

Oct 03, 2025

Oct 03, 2025

Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com

Oct 03, 2025

Oct 03, 2025

Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com

Oct 03, 2025

Oct 02, 2025

Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial - Proactive financial news

Oct 02, 2025

Oct 02, 2025

Tanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADL - MarketBeat

Oct 02, 2025

Sep 30, 2025

H.C. Wainwright reiterates Buy rating on Candel Therapeutics stock at $23 price target - Investing.com Australia

Sep 30, 2025

Sep 30, 2025

H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛

Sep 30, 2025

Sep 29, 2025

HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq

Sep 29, 2025

Sep 29, 2025

CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating | CADL Stock News - GuruFocus

Sep 29, 2025